New and Persistent Sedative-Hypnotic Use after Adjuvant Chemotherapy for Breast Cancer.
Jacob C CoganRohit R RaghunathanMelissa P BeaucheminMelissa K AccordinoYongmei HuangElena B ElkinAlexander MelamedJason D WrightDawn L HershmanPublished in: Journal of the National Cancer Institute (2022)
Patients who receive sedative-hypnotic medications during adjuvant chemotherapy for breast cancer are at risk of becoming new persistent users of these medications after chemotherapy. Providers should ensure appropriate sedative-hypnotic use through tapering dosages and encouraging non-pharmacologic strategies when appropriate.